Advanced Urothelial Carcinoma

Safety, Efficacy of Disitamab Vedotin in Patients With HER2-Positive Locally Advanced or Metastatic UC
A recent combined analysis of 2 phase 2 studies indicates that disitamab vedotin (DV) has promising efficacy and a manageable safety profile in patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic urothelial carcinoma (UC) who had progressed on at least 1 line of prior systemic chemotherapy. The analysis was published in the Journal of Clinical Oncology. ...
Advertisement

Latest News

Advertisement

Urothelial Carcinoma Knowledge Hubs

Curated clinical content based on urothelial cancer types, therapies, and technologies

Urothelial Carcinoma
Urothelial Carcinoma

Conference Coverage

Advertisement
Section Editor

Advertisement
Trending